Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Drops By 18.6%

Repare Therapeutics Inc. (NASDAQ:RPTX) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 609,900 shares, a drop of 18.6% from the October 31st total of 749,700 shares. Based on an average daily trading volume, of 116,000 shares, the days-to-cover ratio is currently 5.3 days. Approximately 2.1% of the shares of the company are sold short.

Repare Therapeutics Stock Down 1.2 %

Shares of NASDAQ:RPTX traded down $0.04 during trading on Friday, reaching $3.28. 96,511 shares of the company traded hands, compared to its average volume of 161,734. The firm has a market capitalization of $139.43 million, a PE ratio of -1.64 and a beta of 0.72. Repare Therapeutics has a 52 week low of $2.71 and a 52 week high of $8.49. The company’s 50 day moving average is $3.38 and its two-hundred day moving average is $3.37.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its stake in Repare Therapeutics by 1,471.7% in the third quarter. Barclays PLC now owns 8,330 shares of the company’s stock valued at $29,000 after acquiring an additional 7,800 shares during the last quarter. Stifel Financial Corp lifted its stake in Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock worth $178,000 after purchasing an additional 13,800 shares during the last quarter. Vontobel Holding Ltd. boosted its holdings in shares of Repare Therapeutics by 20.0% in the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock valued at $83,000 after purchasing an additional 4,000 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after purchasing an additional 8,809 shares during the last quarter. Finally, Blue Owl Capital Holdings LP raised its holdings in shares of Repare Therapeutics by 8.0% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after buying an additional 250,000 shares in the last quarter. Institutional investors and hedge funds own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.